Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairm...(t $22 $22 ...)

Date:2/26/2009

t $22 $22 Less: Income tax expense (a) 3 3 Acquisition-related charges, net of tax $25 $25 Restructuring-related charges: Restructuring-related charges (b) $34 $34 Less: Income tax benefit (a) (7) (7) Restructuring-related charges, net of tax $27 $27 Discrete tax items: Income tax benefit (a) $(109) $(109) Amortization expense: Amortization expense $134 $134 Less: Income tax benefit (8) (8) Amortization expense, net of tax $126 $126 (a) Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Interpretation No. 18, "Accounting for Income Taxes in Interim Periods." (b) Recorded $6 million to cost of products sold; $7 million to selling, general and administrative expenses; $2 million to research and development expenses; and $19 million to restructuring charges. An explanation of the Company's use of these non-GAAP measures is provided at the end of this document

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's financial information presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income and non-GAAP net income per diluted share. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measu
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
2. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
3. Boston Scientific Acquires Labcoat Limited
4. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
5. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
6. Boston Scientific to Participate in Piper Jaffray Health Care Conference
7. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
8. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
9. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
10. InterMune to Present at Deutsche Bank Biotech Boston Confab
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability